Atagi, Shinji

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 750

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 413

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Katakami, N., Atagi, S., Goto, K., Hida, T., Horai, T., Inoue, A., Ichinose, Y., Koboyashi, K., Takeda, K., Kiura, K., et al. (2013) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 326

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Mansfield, A. S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., et al. (2020) · Annals of Oncology

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 193

Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03

Kishida, Y., Kawahara, M., Teramukai, S., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., Nakano, K., et al. (2009) · British Journal of Cancer

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 87

Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer

Maekura, T., Naito, M., Tahara, M., Ikegami, N., Kimura, Y., Sonobe, S., Kobayashi, T., Tsuji, T., Minomo, S., Tamiya, A., et al. (2018) · In Vivo

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 51

Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study

Mok, T. S. K., Wu, Y., Nakagawa, K., Kim, S., Yang, J., Ahn, M., Wang, J., Yang, J. C., Lu, Y., Atagi, S., et al. (2014) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 46